Short answer
TREACE MEDICAL CONCEPTS, INC. (TMCI) filed an 8-K current report with the SEC on November 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for the quarter ended September 30, 2026.
TREACE MEDICAL CONCEPTS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for the quarter ended September 30, 2026
- Exhibit 99.1 contains the company’s detailed results and management commentary for investor review
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $48.3M, down 4% YoY from $50.2M as mix shifted toward lower-priced minimally invasive products
- Procedure volume achieved double-digit growth, while gross margin improved to 79.5% from 79.1%
- Net loss narrowed 23% to $12.6M, and Adjusted EBITDA improved to $0.3M from $(2.6)M
- Cash usage fell 53% year-to-date to $0.7M, with $39.8M in cash, equivalents and marketable securities
- 2026 guidance tightened to $206M-$210M revenue and $1M-$2M Adjusted EBITDA loss, signaling improved profitability expectations despite lower sales growth
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other TREACE MEDICAL CONCEPTS, INC. 8-K filings
Get the next TMCI 8-K as it lands
Follow TMCI for push alerts, or ask the research agent what this filing means.